Galectin Therapeutics Inc. develops therapeutics that target galectin proteins, with its lead program focused on belapectin, a carbohydrate-based galectin-3 inhibitor for MASH cirrhosis and portal hypertension. Company updates commonly cover NAVIGATE clinical-trial results, biomarker analyses, medical-conference presentations, journal publications, and FDA communications related to the belapectin development program.
News also includes financial results, research and development spending, cash-resource updates, credit financing, board composition, and investor or key-opinion-leader events. Galectin has also described additional development interests in combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics (NASDAQ: GALT) reported a narrower third-quarter 2026 net loss applicable to common stockholders of $3.6 million and updated belapectin development. Loss per share was $0.04 versus $0.13 a year earlier. Research and development expenses fell to $1.6 million from $2.6 million; administrative expenses rose to $1.8 million from $1.6 million.
Chairman Richard Uihlein converted approximately $105.8 million of debt into 34,376,167 common shares, effective July 31, 2026. September 30 cash was $11.7 million, with $10 million available under a credit line. The company expects funding through June 2027. Galectin submitted its registrational Phase 3 belapectin protocol to the FDA in the third quarter. A NAVIGATE analysis showed a net 15.9% placebo-adjusted improvement in predicted clinically significant portal hypertension risk at 18 months (p=0.04).
Galectin Therapeutics (GALT) will present new belapectin analyses on noninvasive prediction of variceal development at the AASLD Liver Meeting. In NAVIGATE, treatment was associated with a net 15.9% placebo-adjusted improvement toward lower predicted risk of clinically significant portal hypertension, or elevated pressure in the liver's blood vessels, at 18 months (p=0.04). Variceal incidence was lower with belapectin than placebo across baseline ANTICIPATE-NASH and Baveno risk categories.
In Phase 2b GT-026, both noninvasive tools showed only moderate agreement with invasive pressure measurements; Baveno VII performed slightly better. Galectin plans to use noninvasive risk assessments to select higher-risk patients for its planned Phase 3 registration trial. The company has submitted the Phase 3 protocol to the FDA and is advancing trial initiation activities while evaluating partnerships.
Galectin Therapeutics (NASDAQ: GALT) has submitted a registrational Phase 3 trial protocol for belapectin to the U.S. Food and Drug Administration.
The proposed trial addresses prevention of disease progression in patients with MASH cirrhosis and portal hypertension, or elevated pressure in the portal vein. The company will also present noninvasive risk analyses from the NAVIGATE and GT-026 Phase 2b trials at the AASLD Liver Meeting, November 5–9, 2026, in Denver. The presentations examine prediction of variceal development and relationships between noninvasive models and hepatic venous pressure measurements.
Galectin Therapeutics (GALT) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 11:30 AM ET in New York. The appearance will include a formal company presentation and one-on-one investor meetings, with a live and archived webcast accessible through the conference link and the Events & Presentations page in Galectin’s investor section.
Galectin develops therapeutics targeting galectin proteins, led by belapectin, a galectin-3 inhibitor with U.S. FDA Fast Track designation. The lead program focuses on metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension, and additional clinical work is underway in combination immunotherapy for advanced head and neck cancers and other malignancies, with further progress in these areas largely dependent on securing suitable partners.
Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results and a business update for the period ended June 30, 2026. The company reached agreement with the FDA on key elements of its planned registrational Phase 3 trial of belapectin in advanced MASH cirrhosis with portal hypertension, including a composite liver outcome primary endpoint, blinded central endoscopy review and a single 2 mg/kg LBM dose. Protocol submission is anticipated in 3Q 2026.
New NAVIGATE Phase 2b/3 analyses were presented at EASL and published in Hepatology and Gastro Hep Advances. Chairman Richard Uihlein converted approximately $105.8 million of principal and accrued interest into 34.4 million shares, eliminating that debt. Q2 R&D was $2.1 million, G&A $1.8 million, and net loss applicable to common stockholders was $9.2 million ($0.14 per share). Cash was $13.2 million, with sufficient liquidity projected through June 2027 and $10 million remaining on a credit line.
Galectin Therapeutics (NASDAQ: GALT) announced that Chairman and largest stockholder Richard E. Uihlein has converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock, effective July 31, 2026. The transaction eliminates approximately $105.8 million in total debt obligations, consisting of $91.0 million in principal and about $14.8 million in accrued interest, in exchange for 34,376,167 newly issued shares.
The notes were converted at their individual conversion prices, with a blended average of about $3.07 per share, subject to a $3.00 floor. Following the conversion, Galectin had 100,849,644 shares outstanding. A separate December 19, 2025 supplemental credit facility of up to $10 million remains undrawn and available. The shares were issued under a Section 3(a)(9) Securities Act exemption, and Galectin is obligated to register the resale of the new shares within 180 days.
Galectin Therapeutics (NASDAQ:GALT) reported positive Type C FDA feedback on belapectin for patients with MASH cirrhosis and portal hypertension.
The FDA agreed on a composite liver outcome primary endpoint, accepted a blinded central endoscopy review, and indicated that a single, adequate Phase 3 trial may support a traditional full approval pathway. Galectin plans to file the Phase 3 protocol in Q3 2026 and is seeking strategic and financial partners.
Galectin Therapeutics (NASDAQ:GALT) reported new NAVIGATE trial analyses at EASL 2026 showing belapectin’s potential to modify disease progression in advanced MASH cirrhosis and portal hypertension.
Belapectin 2 mg/kg reduced new varices, lessened liver stiffness worsening, improved Baveno risk category, and modulated fibrogenesis markers, with a TOP Poster and data published in Hepatology.
Galectin Therapeutics (NASDAQ:GALT) reported Q1 2026 results and a belapectin program update. Net loss was $5.1 million ($0.08/share), improved from $9.6 million in Q1 2025. Cash was $14.1 million, plus $10 million available under a credit line, which the company believes funds operations through May 2027.
In the NAVIGATE Phase 2b/3 trial in MASH cirrhosis, belapectin 2 mg/kg showed statistically significant reductions in liver stiffness and fewer patients with >30% increases vs placebo. Upcoming catalysts include EASL 2026 data presentations and an FDA Type-C meeting in Q2 2026.
Galectin Therapeutics (NASDAQ:GALT) reported publication of Phase 2b NAVIGATE trial results for galectin-3 inhibitor belapectin in Journal of Hepatology. The study in patients with MASH cirrhosis and portal hypertension showed belapectin 2 mg/kg reduced new esophageal varices numerically versus placebo, with statistical significance in the per-protocol population and supportive fibrosis/portal hypertension biomarkers, alongside a favorable safety profile.